OrthoPediatrics announced it has received 510(k) clearance from the U.S. Food and Drug Administration FDA for its Pediatric Nailing Platform Tibia surgical system. Part of the Trauma & Deformity Correction suite of products, PNP Tibia represents another pediatric-focused solution for treating patients with fractures and deformities in the lower extremities. It expands the Company’s offering to 51 unique surgical systems designed specifically to help treat the needs of pediatric patients and is expected to launch in the third quarter of 2023. The PNP Tibia System features rigid cannulated nails, ranging in diameters from 7mm-12mm, and includes specialized instrumentation to facilitate multiple surgical techniques. Like other OrthoPediatrics products, this system was designed for children’s anatomy and growing patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Receives FDA 510(k) Clearance for Pediatric Nailing Platform | Tibia
- OrthoPediatrics management to meet virtually with BTIG
- OrthoPediatrics price target lowered to $51 from $57 at Truist
- OrthoPediatrics sees FY23 revenue $148M-$151M, consensus $149.28M
- OrthoPediatrics reports Q2 EPS (19c), consensus (22c)